ArticleGynecologic oncology reports2026
Molecular subtypes of stage III vulvar squamous cell carcinoma predict recurrence and survival outcomes.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although molecular classification has been associated with outcomes in vulvar squamous cell carcinoma (vSCC), its relevance in patients with stage III disease is less well characterized. We evaluated the association between molecular subtype and oncologic outcomes among patients with 2021 FIGO stage III vSCC. Methods: We conducted a retrospective study of patients with primary stage III vSCC treated at a single institution from 2000 to 2021. Tumors were classified as HPV-associated (HPV+), HPV-independent/p53 wild-type (HPV-/p53wt), or HPV-independent/p53 mutant (HPV-/p53mut) using HPV RNA in situ hybridization and p16 immunohistochemistry (IHC) for HPV status and p53 IHC as a surrogate for TP53 mutation status. Primary outcomes were recurrence and disease-specific mortality within five years from primary treatment evaluated using Cox proportional hazards and Kaplan-Meier survival analysis. Results: Fifty-two patients had complete molecular data: 32.7% HPV+, 21.2% HPV-/p53wt, and 46.2% HPV-/p53mut. Smoking was associated with HPV+ tumors ( Conclusions: Molecular classification distinguishes clinically meaningful subgroups in stage III vSCC. HPV-independent tumors, particularly those with TP53 mutation, are associated with worse disease-specific survival and supports further evaluation of molecularly informed risk stratification and treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.